Last reviewed · How we verify
NCT06322927: iPREFER
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
trial testing Patient Interview in Multiple Myeloma in 9 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | The Christie NHS Foundation Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 5 April 2024 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Patient Interview
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
The Christie NHS Foundation Trust
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study.
Perry MB, Lochhead Devaraj R, Law K, Ashby F, et al · · 2026 · PMID 42080199 · DOI 10.2147/ppa.s576524
Verify or expand the search:
- PubMed search for NCT06322927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Patient Interview
Trials testing the same drug.
- NCT04264845 — Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure · completed
- NCT03546023 — Brief Pain Inventory to Assess Cancer Pain and Quality of Life · completed
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other The Christie NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
- NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
- NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
- NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
- NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06322927 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06322927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing